The TIL therapy that selects for the cells that recognize the tumor
AgonOx isolates and expands the CD39+CD103+ subset of a patient's tumor-infiltrating lymphocytes, the fraction that is genuinely tumor-reactive. Our lead program, AGX-148, is in Phase 1 in solid tumors, with additional cell therapy programs in IND-enabling studies
